Genmab A/S (LTS:0MGB)

kr 1839.5 -9.25 (-0.5%) Market Cap: 117.16 Bil Enterprise Value: 88.58 Bil PE Ratio: 22.31 PB Ratio: 3.70 GF Score: 88/100

Q1 2024 Genmab A/S Earnings Call Transcript
May 02, 2024

kr1944.25 (-1.37%)

Earnings
Genmab A/S Annual Shareholders Meeting Transcript
Mar 13, 2024
Q4 2023 Genmab A/S Earnings Call Transcript
Feb 14, 2024

kr1874.25 (+1.17%)

Earnings
Genmab A/S at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Genmab A/S R&D Update and ASH Data Review Transcript
Dec 12, 2023
Q3 2023 Genmab A/S Earnings Call Transcript
Nov 07, 2023

kr2018.75 (-0.15%)

Earnings
Genmab A/S at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2023
Half Year 2023 Genmab A/S Earnings Call Transcript
Aug 03, 2023

kr2637.5 (-1.66%)

Earnings
Genmab A/S at Goldman Sachs Healthcare Conference Transcript
Jun 13, 2023
Q1 2023 Genmab A/S Earnings Call Transcript
May 10, 2023

kr2721 (+1.53%)

Earnings
Genmab A/S Annual Shareholders Meeting Transcript
Mar 29, 2023
Q4 2022 Genmab A/S Earnings Call Transcript
Feb 22, 2023

kr2737 (-0.87%)

Earnings
Genmab A/S at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Genmab A/S R&D Update and ASH Data Review Transcript
Dec 13, 2022
Q3 2022 Genmab A/S Earnings Call Transcript
Nov 09, 2022

kr2985.5 (+0.42%)

Earnings
Genmab A/S at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022
Q2 2022 Genmab A/S Earnings Call Transcript
Aug 10, 2022

kr2567.5 (-0.12%)

Earnings
Genmab A/S at Goldman Sachs Global Healthcare Conference Transcript
Jun 15, 2022
Q1 2022 Genmab A/S Earnings Call Transcript
May 11, 2022

kr2075.5 (-0.17%)

Earnings
Genmab A/S Annual Shareholders Meeting Transcript
Mar 29, 2022
Q4 2021 Genmab A/S Earnings Call Transcript
Feb 16, 2022

kr2226.5 (+1.44%)

Earnings
Genmab A/S at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 12, 2022
Genmab A/S Virtual R&D Update and ASH Data Review Transcript
Dec 14, 2021
Q3 2021 Genmab A/S Earnings Call Transcript
Nov 10, 2021

kr2767.5 (-6.09%)

Earnings
Genmab A/S at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 09, 2021
Q2 2021 Genmab A/S Earnings Call Transcript
Aug 11, 2021

kr2861.5 (-0.23%)

Earnings
Genmab A/S at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 09, 2021
Q1 2021 Genmab A/S Earnings Call Transcript
May 05, 2021

kr2215 (-1.09%)

Earnings
Genmab A/S Annual Shareholders Meeting Transcript
Apr 13, 2021
Q4 2020 Genmab A/S Earnings Call Transcript
Feb 23, 2021

kr2291 (-3.78%)

Earnings
Genmab A/S at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Genmab A/S Virtual 2020 ASH Data Review Meeting Transcript
Dec 08, 2020
Genmab A/S Virtual Capital Markets Day Transcript
Nov 13, 2020
Q3 2020 Genmab A/S Earnings Call Transcript
Nov 04, 2020

kr2324.5 (+6.43%)

Earnings
Genmab A/S at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 15, 2020
Q2 2020 Genmab A/S Earnings Call Transcript
Aug 12, 2020

kr2269 (-2.03%)

Earnings
Genmab A/S at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 11, 2020
Genmab A/S to Discuss Broad Oncology Collaboration with Abbvie Inc Call Transcript
Jun 10, 2020
Q1 2020 Genmab A/S Earnings Call Transcript
May 06, 2020

kr1721.5 (+2.17%)

Earnings
Genmab A/S Annual Shareholders Meeting Transcript
Mar 26, 2020
Genmab A/S at PR Newswire and BetterInvesting (NAIC) Deutsche Bank Depositary Receipts Virtual Investor Conference Transcript
Mar 18, 2020
Q4 2019 Genmab A/S Earnings Call Transcript
Feb 19, 2020

kr1632.5 (-2.27%)

Earnings
Genmab A/S at JPMorgan Healthcare Conference Transcript
Jan 15, 2020
Genmab A/S 2019 R&D Update and ASH Data Review Meeting Transcript
Dec 10, 2019
Q3 2019 Genmab A/S Earnings Call Transcript
Nov 06, 2019

kr1467 (+0.91%)

Earnings
Q2 2019 Genmab A/S Earnings Call Transcript
Aug 14, 2019

kr1306.75 (-0.34%)

Earnings
Q1 2019 Genmab A/S Earnings Call Transcript
May 08, 2019

kr1114.5 (+1.00%)

Earnings
Q4 2018 Genmab A/S Earnings Call Transcript
Feb 20, 2019

kr1002 (+0.48%)

Earnings

Genmab A/S R&D Update and ASH Data Review Transcript

Dec 12, 2023 / 04:00PM GMT

Release Date Price: kr2069.5 (-6.72%)

Transcript

Jan G.J. van de Winkel;S;Co;Founder

Genmab A;President & CEO

/-- -

Hello, and welcome to Genmab's 2023 R&D Update and ASH Data Review. I'm Jan van de Winkel, President and CEO of Genmab, and I'm delighted to share with you some of the highlights for Genmab in 2023 as well as data from this year's ASH meeting. As always, we have a busy agenda. So, let's jump right in.

Next slide, please. As a reminder, this presentation may contain forward-looking statements, and as such, may contain certain risks and uncertainties.

Let's move to Slide 3. Genmab has a science-anchored and innovation-focused culture. Collaborations and partnerships have always been part of our DNA. During today's presentation, we will reference some of the products being developed under these strategic collaborations and this slide acknowledges those relationships.

Let's move to our agenda on Slide 4. We will begin with a review of the excellent progress we made this year, as we advance towards our ambitious 2030 vision. Next, we will have a

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.